"We will be restructuring parts of the business and reducing our overall spend, which we expect to extend our existing cash runway into 2028 and provide greater flexibility," Rowland wrote.
"The layoffs come after a 'portfolio review' at Grail, according to Rowland, which sparked the company to devote more resources to its multi-cancer, early-detection test, Galleri."
"The Galleri screening test requires a single draw of blood and analyzes it for cancer signals; it's available via prescription, but not covered by most insurance plans."
Collection
[
|
...
]